Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cumulative changes in mTSS for SB2 and infliximab

Published byὝδρα Ιωάννου Modified over 5 years ago

Similar presentations

Presentation on theme: "Cumulative changes in mTSS for SB2 and infliximab"— Presentation transcript:

1 Cumulative changes in mTSS for SB2 and infliximab
Cumulative changes in mTSS for SB2 and infliximab. Values are presented as mean (SD) in patients with available mTSS at both baseline and week 54. Cumulative changes in mTSS for SB2 and infliximab. Values are presented as mean (SD) in patients with available mTSS at both baseline and week 54. INF, infliximab; mTSS, modified Total Sharp Score. Thomas Dörner et al. Considerations Med 2017;1:7-12 ©2017 BMJ Publishing Group Ltd and CESAS Publications Ltd

Download ppt "Cumulative changes in mTSS for SB2 and infliximab"

Similar presentations

 Categorisation of direct and indirect admissions to the intensive care unit (ICU) from emergency departments (EDs), using source of admission.  Categorisation.

 Categorisation of direct and indirect admissions to the intensive care unit (ICU) from emergency departments (EDs), using source of admission.  Categorisation.
Patients included in linear extrapolation and observed/last observation carried forward analyses at week 48. Patients who were rescued or discontinued.

Patients included in linear extrapolation and observed/last observation carried forward analyses at week 48. Patients who were rescued or discontinued.
Changes in physical fitness between baseline, 3-month and 12-month follow-up: (A) Mobility limitations in neck-shoulder area; % with severe limitations,

Changes in physical fitness between baseline, 3-month and 12-month follow-up: (A) Mobility limitations in neck-shoulder area; % with severe limitations,
Bland-Altman plot comparing average steps/day over a 7-day period for the Fitbit tracker and ActiGraph accelerometer. Bland-Altman plot comparing average.

Bland-Altman plot comparing average steps/day over a 7-day period for the Fitbit tracker and ActiGraph accelerometer. Bland-Altman plot comparing average.
Bland-Altman plots comparing step counts over a 2 min walk test for the Fitbit tracker, ActiGraph accelerometer and visual count by a physiotherapist.

Bland-Altman plots comparing step counts over a 2 min walk test for the Fitbit tracker, ActiGraph accelerometer and visual count by a physiotherapist.
Chart 3: Working example of oxygen section for hospital prescription charts (two panels are required on the prescription chart because oxygen may change.

Chart 3: Working example of oxygen section for hospital prescription charts (two panels are required on the prescription chart because oxygen may change.
 Trends in incidence rates of reported work related injuries and illnesses in jobs with and without exposure, for two exposure categories (hours/week and.

 Trends in incidence rates of reported work related injuries and illnesses in jobs with and without exposure, for two exposure categories (hours/week and.
A, B, C, D show outcome results for individual symptoms using GSRS-IBS scoring system and mean symptom severity scores before and after IBS dietetic management.

A, B, C, D show outcome results for individual symptoms using GSRS-IBS scoring system and mean symptom severity scores before and after IBS dietetic management.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
Effect of confidence interval reduction to demonstrate a true difference in means. Effect of confidence interval reduction to demonstrate a true difference.

Effect of confidence interval reduction to demonstrate a true difference in means. Effect of confidence interval reduction to demonstrate a true difference.
Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.

Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.
The proposed new evidence-based medicine pyramid.

The proposed new evidence-based medicine pyramid.
Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.
Harvest plot of intervention effects on muscle physical activity levels. Harvest plot of intervention effects on muscle physical activity levels. Each.

Harvest plot of intervention effects on muscle physical activity levels. Harvest plot of intervention effects on muscle physical activity levels. Each.
Baseline Characteristics of the Study Participants

Baseline Characteristics of the Study Participants
Interpretation of results presented as heat maps and heat map results for the exercise subtests, ranked by the total Functional Movement Screen (FMS) score.

Interpretation of results presented as heat maps and heat map results for the exercise subtests, ranked by the total Functional Movement Screen (FMS) score.
OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,
Each circle represents the outcome of one patient, but sometimes the circles are very close or even merge. Each circle represents the outcome of one patient,

Each circle represents the outcome of one patient, but sometimes the circles are very close or even merge. Each circle represents the outcome of one patient,
Percentage change in mean subscale score for nausea/vomiting (A), postprandial fullness/early satiety (B) and bloating (C) for all patients (n=23) and.

Percentage change in mean subscale score for nausea/vomiting (A), postprandial fullness/early satiety (B) and bloating (C) for all patients (n=23) and.
A, B, C, D show outcome results for individual symptoms using GSRS-IBS scoring system and mean symptom severity scores before and after IBS dietetic management.

A, B, C, D show outcome results for individual symptoms using GSRS-IBS scoring system and mean symptom severity scores before and after IBS dietetic management.

Similar presentations

Ads by Google